BioSpace News Archive

Infinimmune announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company’s Board of Directors.

Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.

Bausch Health Companies Inc. announced the results of its 2024 annual meeting of shareholders.

Ainos, Inc. today announced the initiation of a clinical study for a new potential VELDONA®-based drug for pet disease.

Calliditas Therapeutics AB today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26, 2024.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting.

Researchers from Lund University and Enable Biosciences announced significant findings from their latest collaborative study, revealing the superior performance of the automated multiplex Antibody Detection by Agglutination-PCR technology over traditional Radiobinding Assays in identifying early stages of Type 1 Diabetes.

Thermo Fisher Scientific Introduces Array-based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions.

Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.

EVŌQ Bio, a wholly-owned subsidiary of EVŌQ Nano, today announced the successful completion of a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the preclinical and clinical development plan for an inhaled therapeutic to treat pulmonary bacterial infections.